Fresenius Medical Care stock: 500 million euro bond set to settle Nov. 16

Fresenius Medical Care placed a 500 million euro bond on Monday, November 9, 2026, according to the company's official press release. Fresenius Medical Care stock traded at 39.87 euros on Lang & Schwarz at 12:02 CET on Friday, November 13, 2026, 0.78% above the Xetra close of Thursday, November 12.

Financing terms set through 2032

The bond matures in February 2032 and carries a fixed annual coupon of 4.250%. Fresenius Medical Care issued it at 99.497% of face value, producing a yield of 4.363% per year.

The company said the proceeds will be used for general corporate purposes, including refinancing existing financial liabilities. The issue therefore addresses funding and liability management rather than a disclosed acquisition or a specific expansion project.

Settlement is planned for November 16

The bond was issued under Fresenius Medical Care's Debt Issuance Programme. The company has applied for admission to trading on the regulated market of the Luxembourg Stock Exchange, with settlement scheduled for Monday, November 16, 2026.

The planned settlement is the next transaction milestone. Until then, the announced terms define the financing cost, while the stated use of proceeds leaves the precise liabilities to be refinanced unspecified.

Business context remains healthcare focused

Fresenius Medical Care describes itself as a provider of products and services for people with renal diseases. The company says around 4.5 million patients worldwide regularly undergo dialysis, while its network comprises 3,512 dialysis clinics serving approximately 290,000 patients. It also supplies dialysis products, including machines and dialyzers.

The financing announcement comes after the company reported third-quarter 2026 performance on November 3 and narrowed its full-year outlook, according to the newsroom listing. The bond does not by itself establish how operating performance or future cash flow will develop, but it gives investors a defined refinancing timetable and a fixed coupon through the February 2032 maturity.

European healthcare shares remain sensitive to financing costs and reimbursement expectations. See current DAX market reports for the wider German equity setting.

More news and analyses on Fresenius Medical Care stock.